HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
Stocks · News reference
DiaMedica Says It Will Present Interim Data From First Six Patients In Phase 2 DM199 Fetal Growth Restriction Trial October 23
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — DiaMedica Therapeutics Inc. (DMAC)
Filed: 2026-08-10 AccNo: 0001437749-26-026790 Size: 490 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of $(0.18) per share